Oncimmune's EarlyCDT Lung test has been found to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.
Researchers have developed a novel technology that could sensitively detect and classify cancer cells, as well as determine disease aggressiveness, from the least invasive biopsies.
By measuring intact living cancer cells in the patient's blood, rather than the PSA protein, the method potentially provides a more accurate test for prostate cancer.
Eye-tracking technology could be used in future to predict if people with mild memory and thinking impairments will go on to develop Alzheimer's disease.
The 'two-in-one' test not only detects the type of HPV infection but also indicates precancerous markers.
The test could soon result in tailored treatment for women with invasive lobular breast cancer, in some cases relieving patients from the gruelling process of undergoing chemotherapy.
A virus scanner for a smartphone might not sound too exciting at first, but the device in question doesn't search for the latest malware; it scans biological samples for real viruses.
Electronic voltammetric tongues could help detect bladder cancer in its earliest stages with a small urine sample.
The renal probes are injected into the bloodstream and light up when they detect molecular changes caused by the onset of acute kidney failure.
Researchers from both Singapore and Sweden have, within a day of each other, announced their own blood tests for Alzheimer's disease.
A computer-assisted diagnostic procedure helps physicians detect the growth of low-grade brain tumours earlier and at smaller volumes than visual comparison alone.
US scientists have found a way to differentiate the subset of patients with prostate cancer who require more aggressive management and treatment.
European researchers have found a way to identify hospital patients with suspected sepsis infection who may suffer from subsequent disease progression.
Thermo Fisher Scientific has entered into a collaboration with NX Prenatal to develop proteomics assays to monitor foetal health in utero and assess the risk of adverse outcomes.
Swedish scientists have shown how a blood test can reveal whether there is accelerating nerve cell damage in the brain.